Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9550648 | 0.98 | TRPV1 (0.54) | TRPV1FAAHCA1LMNACNR1 | |
| SCHEMBL10793127 | 0.86 | TRPV1 (0.43) | TRPV1FAAHLMNATSHR | |
| SCHEMBL10793139 | 0.86 | TRPV1 (0.43) | TRPV1FAAHLMNATSHR | |
| SCHEMBL10793131 | 0.86 | TRPV1 (0.43) | TRPV1FAAHLMNATSHR | |
| SCHEMBL9805289 | 0.85 | TRPV1 (0.56) | TRPV1FAAHCA1LMNACNR1 | |
| SCHEMBL9623261 | 0.83 | TRPV1 (0.50) | TRPV1FAAHCA1LMNACNR1 | |
| SCHEMBL14396088 | 0.81 | TRPV1 (0.53) | TRPV1FAAHCA1LMNACNR1 | |
| SCHEMBL12611049 | 0.81 | PTPN1 (0.49) | TRPV1FAAHLMNAGPR84FFAR1 | |
| SCHEMBL18595115 | 0.81 | FAAH (0.47) | TRPV1FAAHCA1LMNACNR1 | |
| SCHEMBL27273674 | 0.81 | TRPV1 (0.42) | TRPV1FAAHLMNACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | TRPV1 4537/4885FAAH 854/4885CA1 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.